Phospho-BCL9L (Ser915) Polyclonal Antibody | Invitrogen PA5-104575 product information

This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.

product summary

company name :

Invitrogen

other brands :

NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience

product type :

antibody

product name :

Phospho-BCL9L (Ser915) Polyclonal Antibody

catalog :

PA5-104575

quantity :

100 uL

price :

US 464.00

clonality :

polyclonal

host :

domestic rabbit

conjugate :

nonconjugated

reactivity :

human, mouse, rat

application :

western blot, immunohistochemistry, immunocytochemistry, immunohistochemistry - paraffin section

product information

Product Type :

Antibody

Product Name :

Phospho-BCL9L (Ser915) Polyclonal Antibody

Catalog # :

PA5-104575

Quantity :

100 uL

Price :

US 464.00

Clonality :

Polyclonal

Purity :

sequential chromatography

Host :

Rabbit

Reactivity :

Human, Mouse, Rat

Applications :

Immunocytochemistry: 1:100-1:500, Immunohistochemistry (Paraffin): 1:50-1:200, Western Blot: 1:500-1:2,000

Species :

Human, Mouse, Rat

Isotype :

IgG

Storage :

-20 C

Description :

Bcl9L, a homolog of Bcl9, was initially identified through a bioinformatics screening. It is expressed in fetal brain, adult lung, eye and prostate, in addition to several types of tumors including pancreatic and prostate cancers. Bcl9L has been shown to interact with beta-catenin, a target of the Wnt signaling pathway, and is required for enhanced beta-catenin-T-cell factor (TCF)-mediated transcription in colorectal tumor cells, possibly by translocating beta-catenin to the nucleus. Other studies have indicated that Bcl9L expression correlates with high nuclear grade cancer phenotype and the expression of ErbB2/HER-2 in breast cancers, suggesting that activity may occur in other types of cancer. Bcl9L has also been shown to be critical for Wnt-mediate regulation of stem cell traits in colon epithelium and adenocarcinomas which are associated with tumor invasion, metastasis, and resistance to therapy.

Immunogen :

A synthesized peptide derived from human BCL9L(Accession Q86UU0), corresponding to amino acid residues around phosphorylated Ser915.

Format :

Liquid

Applications w/Dilutions :

Immunocytochemistry: 1:100-1:500, Immunohistochemistry (Paraffin): 1:50-1:200, Western Blot: 1:500-1:2,000

Aliases :

B cell CLL/lymphoma 9-like; B9L; BC003321; B-cell CLL/lymphoma 9-like; B-cell CLL/lymphoma 9-like protein; B-cell lymphoma 9-like protein; BCL9-2; BCL9L; BCL9-like protein; BCL9-related beta-catenin-binding protein; DLNB11; nuclear co-factor of beta-catenin signalling; protein BCL9-2